Themis Bioscience
Biotechnology company that developed novel vaccines for high burden infectious diseases and oncology applications using a measles virus vector platform. Acquired by Merck in 2020.
Notes
Themis Bioscience was a biotechnology company developing novel vaccines for high burden infectious diseases and oncology applications. The company was headquartered in Vienna, Austria.
Themis's proprietary vaccine platform was based on a measles virus vector that could be engineered to express antigens from various pathogens. This platform was used to develop vaccines for:
- Chikungunya virus
- COVID-19 (in partnership with Institut Pasteur)
- Other infectious diseases
- Cancer immunotherapy
Acquired by Merck (MSD) in June 2020 as part of Merck's strategy to expand its vaccine pipeline and capabilities. The acquisition gave Merck access to Themis's measles virus vector platform and its COVID-19 vaccine candidate.
Team
- Historical leadership (company acquired in 2020)
- Erich Tauber - Former Chief Executive Officer
Additional Research Findings
- Measles virus vector vaccine platform
- Founded in 2009
- Vienna, Austria headquarters
- Acquired by Merck (MSD) in June 2020
- COVID-19 vaccine development (with Institut Pasteur)
- Chikungunya vaccine program
- Oncology vaccine applications
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |